CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 127 enrolled
Drug / intervention
fluticasone propionate (FP) +1 moredrug
Likely dose
fluticasone propionate (FP) 200 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00398476
NCT00398476Phase 3Completed
CompareCT.gov

A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Fluticasone Propionate Aqueous Nasal Spray in Subject With Allergic Rhinitis

GlaxoSmithKline·interventional·Posted Nov 10, 2006·Updated Mar 1, 2018

In Brief

A Phase 3 clinical trial evaluating fluticasone propionate (FP) and fluticasone furoate (FF) for Rhinitis, Allergic, Perennial. Completed, enrolled 127 participants across 14 sites.

Detailed Summary

The objectives of this study are to evaluate and compare patient preference for FF (Fluticasone Furoate) and FP (Fluticasone Propionate Aqueous)nasal sprays in the treatment of allergic rhinitis following single-dose administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Allergic, Perennial
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 10, 2006
Enrollment StartDec 1, 2006
Primary CompletionDec 4, 2006
TodayJul 2, 2026
Enrollment to primary: 3 daysPosted 19.6 years ago

Interventions

fluticasone propionate (FP)drug

200 micrograms (mcg); an aqueous suspension of microfine FP

fluticasone furoate (FF)drug

110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF